BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25791818)

  • 1. Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells.
    Noma N; Asagiri M; Takeiri M; Ohmae S; Takemoto K; Iwaisako K; Minato N; Maeda-Yamamoto M; Simizu S; Umezawa K
    Int Arch Allergy Immunol; 2015; 166(2):84-90. PubMed ID: 25791818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of MMP-2-mediated cellular invasion by NF-κB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: A model for early phase of metastasis.
    Ukaji T; Lin Y; Okada S; Umezawa K
    Biochem Biophys Res Commun; 2017 Mar; 485(1):76-81. PubMed ID: 28188787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
    Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
    Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
    Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Suzuki E; Umezawa K
    Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.
    Suzuki E; Sugiyama C; Umezawa K
    Biomed Pharmacother; 2009 Jun; 63(5):351-8. PubMed ID: 18635336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
    Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
    Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
    Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
    Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
    Sato M; Nakanishi K; Haga S; Fujiyoshi M; Baba M; Mino K; ; Niwa H; Yokoo H; Umezawa K; Ohmiya Y; Kamiyama T; Todo S; Taketomi A; Ozaki M
    Oncol Res; 2013; 21(6):333-43. PubMed ID: 25198663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells.
    Wong JH; Lui VW; Umezawa K; Ho Y; Wong EY; Ng MH; Cheng SH; Tsang CM; Tsao SW; Chan AT
    Cancer Lett; 2010 Jan; 287(1):23-32. PubMed ID: 19560263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.
    Watanabe M; Yamashita K; Kamachi H; Kuraya D; Koshizuka Y; Shibasaki S; Asahi Y; Ono H; Emoto S; Ogura M; Yoshida T; Ozaki M; Umezawa K; Matsushita M; Todo S
    Transplantation; 2013 Sep; 96(5):454-62. PubMed ID: 23860082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
    Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
    Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow.
    Ohno O; Shima Y; Ikeda Y; Sakurai K; Watanabe K; Kawai Y; Umezawa K
    Oncol Res; 2005; 15(4):189-97. PubMed ID: 17822279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
    Nakajima S; Kato H; Gu L; Takahashi S; Johno H; Umezawa K; Kitamura M
    J Immunol; 2013 Jun; 190(12):6559-69. PubMed ID: 23690471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.